Akebia Therapeutics, Inc.
AKBA
$2.06
$0.168.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.80% | -133.50% | 52.28% | -3,029.15% | 104.24% |
| Total Depreciation and Amortization | 44.47% | -0.38% | 0.37% | -31.18% | 44.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.96% | 322.88% | -36.44% | 1,375.81% | -115.98% |
| Change in Net Operating Assets | 57.79% | 43.89% | 9.93% | 6.53% | -285.31% |
| Cash from Operations | 33.29% | 33.49% | 48.20% | -741.94% | 67.80% |
| Capital Expenditure | 0.00% | 93.10% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | 93.10% | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -78.38% | -- | -- |
| Total Debt Repaid | -- | 100.00% | 98.98% | -359.08% | -- |
| Issuance of Common Stock | 1,179.31% | 12,364.29% | -99.93% | 182.43% | 13,320.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Financing | 1,725.43% | -83.99% | -58.65% | 1,532.17% | -2,680.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 426.21% | -122.97% | -156.53% | 73.40% | 49.44% |